- Home
- BTOG vs RLMD Comparison
BTOG vs RLMD Comparison
Compare BTOG & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTOG
- RLMD
- Stock Information
- Founded
- BTOG 2018
- RLMD 2004
- Country
- BTOG Singapore
- RLMD United States
- Employees
- BTOG N/A
- RLMD N/A
- Industry
- BTOG Finance: Consumer Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- BTOG Finance
- RLMD Health Care
- Exchange
- BTOG Nasdaq
- RLMD Nasdaq
- Market Cap
- BTOG 11.0M
- RLMD 11.5M
- IPO Year
- BTOG 2019
- RLMD N/A
- Fundamental
- Price
- BTOG $0.39
- RLMD $0.30
- Analyst Decision
- BTOG
- RLMD Hold
- Analyst Count
- BTOG 0
- RLMD 4
- Target Price
- BTOG N/A
- RLMD $4.25
- AVG Volume (30 Days)
- BTOG 82.5K
- RLMD 2.1M
- Earning Date
- BTOG 01-01-0001
- RLMD 03-18-2025
- Dividend Yield
- BTOG N/A
- RLMD N/A
- EPS Growth
- BTOG N/A
- RLMD N/A
- EPS
- BTOG N/A
- RLMD N/A
- Revenue
- BTOG $2,888,482.00
- RLMD N/A
- Revenue This Year
- BTOG N/A
- RLMD N/A
- Revenue Next Year
- BTOG N/A
- RLMD N/A
- P/E Ratio
- BTOG N/A
- RLMD N/A
- Revenue Growth
- BTOG N/A
- RLMD N/A
- 52 Week Low
- BTOG $0.39
- RLMD $0.28
- 52 Week High
- BTOG $6.39
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- BTOG 27.67
- RLMD 30.81
- Support Level
- BTOG $0.43
- RLMD $0.28
- Resistance Level
- BTOG $0.52
- RLMD $0.36
- Average True Range (ATR)
- BTOG 0.06
- RLMD 0.04
- MACD
- BTOG 0.01
- RLMD 0.02
- Stochastic Oscillator
- BTOG 3.63
- RLMD 7.21
About BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.